PETRUSHKA
Research type
Research Study
Full title
Personalise antidepressant treatment for unipolar depression combining individual choices, risks and big data
IRAS ID
286484
Contact name
Andrea Cipriani
Contact email
Sponsor organisation
University of Oxford/Research Governance, Ethics & Assurance
Clinicaltrials.gov Identifier
Duration of Study in the UK
1 years, 3 months, 1 days
Research summary
Factors influencing an individual’s drug response in major depressive disorder may include a number of clinical variables (such as previous treatments, severity of illness, concomitant anxiety etc.) as well demographics (for instance, age, weight, social support and family history). PETRUSHKA is aimed at developing and subsequently testing a personalised approach to the pharmacological treatment of major depressive disorder in adults, which can be used in everyday NHS clinical settings. We have synthesised data from patients with major depressive disorder, obtained from diverse datasets, including randomised trials as well as observational, real-world studies. These data summarise the highest quality and most up-to-date scientific evidence about benefits and adverse effects of antidepressants for depression and have been used to inform the PETRUSHKA prediction model to produce individualised treatment recommendations. The prediction model underpins a web-based decision support tool (the PETRUSHKA tool) which incorporates patients and clinicians’ preferences, increasing its reliability and tailoring the treatment to each patient. This trial will investigate whether the use of the PETRUSHKA tool is better that treatment as usual in terms of adherence to antidepressant treatment, clinical response and quality of life.
REC name
South Central - Hampshire B Research Ethics Committee
REC reference
22/SC/0240
Date of REC Opinion
22 Aug 2022
REC opinion
Further Information Favourable Opinion